OTCMKTS:DNDNQ

Dendreon (DNDNQ) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
DNDNQ stock logo

About Dendreon Stock (OTCMKTS:DNDNQ)

Dendreon Corporation, is a biotechnology company. The Company is focused on discovery, development and commercialization of therapeutics for cancer treatment. The Company’s product portfolio includes cellular immunotherapies and small molecule product candidate that could be applicable to treating multiple types of cancers. The Company’s product PROVENGE (sipuleucel-T), is an autologous cellular immunotherapy for the treatment of asymptomatic and minimally symptomatic, metastatic, castrate-resistant hormone-refractory prostate cancer. Other potential product candidates include investigational active cellular immunotherapy, which potentially may be used for the treatment of patients with bladder, breast, ovarian and other solid tumors expressing HER2/neu; active cellular immunotherapies directed at carbonic anhydrase 9, an antigen highly expressed in renal cell carcinoma, and carcinoembryonic antigen, an antigen expressed in colorectal and other cancers.

DNDNQ Stock News Headlines

Who is House of Fraser's Yuan Yafei?
Why Dendreon (DNDN) Stock Hit a One-Year Low Today
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
BB Biotech AG
Dendreon Stock Hits New 52-Week Low (DNDN)
Dendreon Stock Gaps Down On Today's Open (DNDN)
Dendreon Will Run on Provenge OK: Poll
The "Smart Money" Is Ready for May 1st Are You?
Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company.
Dendreon: Biotech Stock Mailbag
Dendreon Readies Cost-Cutting Plan
SAC Upped Dendreon Exposure Before Blowup
Dendreon, Ulta Beauty: After-Hours Trading
Dendreon Shares Roiled by Medicare Questions
Dendreon, Vion and Allos: Biotech Mailbag
See More Headlines
Receive DNDNQ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dendreon and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2014
Today
4/24/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
OTCMKTS:DNDNQ
Previous Symbol
NASDAQ:DNDN
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

DNDNQ Stock Analysis - Frequently Asked Questions

How were Dendreon's earnings last quarter?

Dendreon Corporation (OTCMKTS:DNDNQ) released its quarterly earnings results on Monday, November, 10th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.04. The biotechnology company earned $73.10 million during the quarter, compared to the consensus estimate of $78.72 million. The company's quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.44) EPS.

How do I buy shares of Dendreon?

Shares of DNDNQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:DNDNQ) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners